Nektar Therapeutics NKTR Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Nektar Therapeutics's increase decrease in operating lease right of use assets net of operating lease liabilities?
- Nektar Therapeutics (NKTR) reported increase decrease in operating lease right of use assets net of operating lease liabilities of $2.41M in Q1 2026.
- How has Nektar Therapeutics's increase decrease in operating lease right of use assets net of operating lease liabilities changed year-over-year?
- Nektar Therapeutics's increase decrease in operating lease right of use assets net of operating lease liabilities increased by 32.9% year-over-year, from $1.81M to $2.41M.
- What is the long-term trend for Nektar Therapeutics's increase decrease in operating lease right of use assets net of operating lease liabilities?
- Over 3 years (2022 to 2025), Nektar Therapeutics's increase decrease in operating lease right of use assets net of operating lease liabilities has grown at a 78.2% compound annual growth rate (CAGR), from $2.68M to $15.16M.